Researchers track how patients fare on new heart pill
NCT ID NCT05635331
Summary
This study observed 257 patients in Greece who were newly prescribed dapagliflozin for heart failure. The goal was to understand how patients use the medication in real life and how it affects their quality of life. Researchers tracked whether patients continued taking the drug and collected their feedback on symptoms and daily function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Alexandroupoli, 68100, Greece
-
Research Site
Athens, 11526, Greece
-
Research Site
Athens, 11527, Greece
-
Research Site
Athens, 11528, Greece
-
Research Site
Athens, 12462, Greece
-
Research Site
Athens, 14233, Greece
-
Research Site
Athens, 17674, Greece
-
Research Site
Chania, 73300, Greece
-
Research Site
Heraklion, 71409, Greece
-
Research Site
Ioannina, 45445, Greece
-
Research Site
Ioannina, 45500, Greece
-
Research Site
Pátrai, 26504, Greece
-
Research Site
Thessaloniki, 54636, Greece
-
Research Site
Thessaloniki, 54642, Greece
-
Research Site
Thessaloniki, 56429, Greece
-
Research Site
Thessaloniki, 57010, Greece
Conditions
Explore the condition pages connected to this study.